Suscribirse

MOOD DISORDERS AND MENOPAUSE - 10/09/11

Doi : 10.1016/S0889-8529(05)70247-4 
Teri Pearlstein, MD a, b, c, Karen Rosen, MD a, b, Andrea B. Stone, MD d
a Department of Psychiatry and Human Behavior, Brown University School of Medicine (TP, KR) 
b Women's Treatment Program, Butler Hospital (TP, KR) 
c Department of Women's Behavioral Health, Women and Infants' Hospital (TP), Providence, Rhode Island 
d Department of Psychiatry, University of Massachusetts Medical School, Westfield Area Mental Health Center, Westfield, Massachusetts (ABS) 

Resumen

The lifetime prevalence of depression in women in the United States is consistently double the prevalence in men. The increased prevalence in women is also found across countries134 and is true for major depression and milder chronic depression (dysthymia). The Epidemiologic Catchment Area Study reported lifetime prevalence rates of major depression to be 8% in women versus 3.5% in men; lifetime prevalence rates of dysthymia were 5.4% in women versus 2.6% in men.101 The National Comorbidity Survey reported higher lifetime prevalence rates. Major depression occurred at a rate of 21% in women versus 13% in men and dysthymia at a rate of 8% in women versus 5% in men.64 The rates of seasonal affective disorder are higher in women.90 Although the prevalence rates of bipolar disorder (manic-depressive illness) are equal in women and men, women are more likely to have depressive episodes, mixed manic episodes (with depression), and rapid cycling.70 Female gender is clearly associated with an increased risk for affective disorders, particularly, cyclic affective disorders.70, 90

The importance of gender in the expression of depressive disorders is also suggested by the increased rates of depression during the reproductive years. After puberty, the rate of depression rises rapidly in girls relative to boys.63 The premenstrual phase of the menstrual cycle may be associated with an exacerbation of depressive symptoms, may trigger the onset of a depressive episode, or be a time of increased suicidal ideation and psychiatric hospitalization.28 Women with cyclic premenstrual depressive and anxiety symptoms (premenstrual dysphoric disorder) have elevated lifetime prevalence rates of major depression and postpartum depression.94 Although the postpartum period is not always associated with increased rates of depression, women with a previous depression, history of premenstrual dysphoric disorder, or history of bipolar disorder are at increased risk.11 Although many studies do not report increased rates of depression at menopause, the National Comorbidity Survey did find an increased risk of the recurrence of major depression in women aged 45 to 54 years.63 The rates of depression in women decrease after menopause.

The important role of gonadal hormones is suggested by the increased prevalence of depression during the reproductive years and the potential for depressive episodes to occur at times of changes in these hormones. However, the interaction between the hypothalamic-pituitary-gonadal (HPG) axis and mood variables (biologic measures, clinical symptoms, treatment response) is only recently a major focus of research. The expression of depression is also determined by genetic, developmental, psychosocial, and other biologic factors. The complex interaction of these factors at the time of menopause has been previously reviewed.7, 11, 20, 54, 84, 113 This article discusses the association between depression and menopause, the neurobiologic effects of the sex steroids, and the psychologic effects of the clinical use of sex steroids in hormone replacement therapy (HRT).

El texto completo de este artículo está disponible en PDF.

Esquema


 Address reprint requests to Teri Pearlstein, MD, Butler Hospital, 345 Blackstone Boulevard, Providence, RI 02906


© 1997  W. B. Saunders Company. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 26 - N° 2

P. 279-294 - juin 1997 Regresar al número
Artículo precedente Artículo precedente
  • THE MENOPAUSE TRANSITION
  • Gail A. Greendale, MaryFran Sowers
| Artículo siguiente Artículo siguiente
  • THE PATHOPHYSIOLOGY AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS : An Evidence-Based Approach to Estrogen Replacement Therapy
  • Clifford J. Rosen, Cathy R. Kessenich

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.